Innovative Fully-Connected Continuous Manufacturing™ technology and advanced facilities are revolutionizing biomanufacturing and driving cost efficiency, especially in monoclonal antibody production.
Russell Miller
Advertisement
Articles by Russell Miller
Advertisement
Latest Updated Articles
Fully-Connected Continuous Manufacturing™ as the Key to Cost Efficiency and Scalability in BiotechPublished: April 22nd 2025 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
2
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
5
